ADC THERAPEUTICS RSS Feed | Nachrichten - www.finanzen.netwww.finanzen.net bietet Finanznachrichten zum weltweiten BörsengeschehenFinanzenhttps://www.finanzen.netde-definanzen.net GmbHSat, 04 Apr 2026 15:25:20 +0200https://images.finanzen.net/images/finanzen_net_neu.gifADC THERAPEUTICS RSS Feed | Nachrichten - www.finanzen.nethttps://www.finanzen.netADC Therapeutics: Was beim Unternehmen in den jüngsten Büchern stehtWed, 11 Mar 2026 06:35:06 +0100https://www.finanzen.net/nachricht/aktien/adc-therapeutics-was-beim-unternehmen-in-den-juengsten-buechern-steht-15548042ADC Therapeutics hat in der Finanzkonferenz zum Quartalsende am 10.03.2026 die Bücher zum vergangenen Jahresviertel geöffnet, das am 31.12.2025 abgelaufen war.Der Verlust je Aktie belief sich auf 0,04 USD. ...

]]>https://www.finanzen.net/nachricht/aktien/adc-therapeutics-was-beim-unternehmen-in-den-juengsten-buechern-steht-15548042Ausblick: ADC Therapeutics zieht Bilanz zum jüngsten JahresviertelMon, 09 Mar 2026 07:01:06 +0100https://www.finanzen.net/nachricht/aktien/ausblick-adc-therapeutics-zieht-bilanz-zum-juengsten-jahresviertel-15542681ADC Therapeutics wird am 10.03.2026 die Bilanz für das jüngste Quartal veröffentlichen, das zum 31.12.2025 abgelaufen ist.6 Analysten schätzen im Schnitt, dass ADC Therapeutics ...

]]>https://www.finanzen.net/nachricht/aktien/ausblick-adc-therapeutics-zieht-bilanz-zum-juengsten-jahresviertel-15542681ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate UpdatesThu, 08 Jan 2026 22:05:00 +0100https://www.finanzen.net/nachricht/aktien/adc-therapeutics-provides-preliminary-fourth-quarter-and-full-year-2025-revenue-and-cash-estimates-and-recent-corporate-updates-15403684

Preliminary unaudited fourth quarter and full year 2025 net product revenue of approximately $22M and $73M respectively; cash and cash equivalents ...

]]>https://www.finanzen.net/nachricht/aktien/adc-therapeutics-provides-preliminary-fourth-quarter-and-full-year-2025-revenue-and-cash-estimates-and-recent-corporate-updates-15403684ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare ConferenceThu, 08 Jan 2026 13:15:00 +0100https://www.finanzen.net/nachricht/aktien/adc-therapeutics-to-participate-in-the-44th-annual-j-p-morgan-healthcare-conference-15401864

LAUSANNE, Switzerland, Jan. 8, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ...

]]>https://www.finanzen.net/nachricht/aktien/adc-therapeutics-to-participate-in-the-44th-annual-j-p-morgan-healthcare-conference-15401864ADC Therapeutics Announces New Employee Inducement GrantFri, 02 Jan 2026 22:05:00 +0100https://www.finanzen.net/nachricht/aktien/adc-therapeutics-announces-new-employee-inducement-grant-15389903

LAUSANNE, Switzerland, Jan. 2, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ...

]]>https://www.finanzen.net/nachricht/aktien/adc-therapeutics-announces-new-employee-inducement-grant-15389903INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCTThu, 01 Jan 2026 16:00:00 +0100https://www.finanzen.net/nachricht/aktien/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-adc-therapeutics-sa-adct-15388172

NEW YORK, Jan. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  ...

]]>https://www.finanzen.net/nachricht/aktien/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-adc-therapeutics-sa-adct-15388172INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCTThu, 11 Dec 2025 16:00:00 +0100https://www.finanzen.net/nachricht/aktien/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-adc-therapeutics-sa-adct-15352798

NEW YORK, Dec. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ...

]]>https://www.finanzen.net/nachricht/aktien/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-adc-therapeutics-sa-adct-15352798ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relaps...Wed, 03 Dec 2025 13:30:00 +0100https://www.finanzen.net/nachricht/aktien/adc-therapeutics-announces-updated-data-from-lotis-7-phase-1b-clinical-trial-of-zynlonta-in-combination-with-bispecific-antibody-supporting-potential-best-in-class-regimen-in-patients-with-relaps-15331764

ZYNLONTA® in combination with glofitamab (COLUMVI®) demonstrated an 89.8% ORR and 77.6% CR across the 49 efficacy-evaluable patients with a minimum of 6 months of follow-up

]]>https://www.finanzen.net/nachricht/aktien/adc-therapeutics-announces-updated-data-from-lotis-7-phase-1b-clinical-trial-of-zynlonta-in-combination-with-bispecific-antibody-supporting-potential-best-in-class-regimen-in-patients-with-relaps-15331764ADC Therapeutics to Provide Update on LOTIS-7 Clinical TrialTue, 02 Dec 2025 22:05:00 +0100https://www.finanzen.net/nachricht/aktien/adc-therapeutics-to-provide-update-on-lotis-7-clinical-trial-15329822

Company to host corporate webcast to share updated data on December 3, 2025

LAUSANNE, Switzerland, ...

]]>https://www.finanzen.net/nachricht/aktien/adc-therapeutics-to-provide-update-on-lotis-7-clinical-trial-15329822ADC Therapeutics Makes Grants to New Employees Under Inducement PlanMon, 01 Dec 2025 22:05:00 +0100https://www.finanzen.net/nachricht/aktien/adc-therapeutics-makes-grants-to-new-employees-under-inducement-plan-15326386

LAUSANNE, Switzerland, Dec. 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ...

]]>https://www.finanzen.net/nachricht/aktien/adc-therapeutics-makes-grants-to-new-employees-under-inducement-plan-15326386